Roquefort Therapeutics plc (ROQ.L)
GBp 3.85
(-10.47%)
GBp 3.85
(-10.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.92 Million GBP | -18.32% |
| 2022 | -1.63 Million GBP | -219.97% |
| 2021 | -510.76 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -339.09 Thousand GBP | -172.35% |
| 2024 Q2 | -339.09 Thousand GBP | 0.0% |
| 2023 Q4 | 468.71 Thousand GBP | 194.1% |
| 2023 FY | -1.93 Million GBP | -18.32% |
| 2023 Q3 | -498.1 Thousand GBP | 46.87% |
| 2023 Q2 | -937.44 Thousand GBP | -100.0% |
| 2023 Q1 | -468.71 Thousand GBP | 55.41% |
| 2022 Q1 | -381.14 Thousand GBP | -81.9% |
| 2022 Q4 | -1.05 Million GBP | -141.08% |
| 2022 FY | -1.63 Million GBP | -219.97% |
| 2022 Q3 | -436.01 Thousand GBP | 40.53% |
| 2022 Q2 | -733.11 Thousand GBP | -92.35% |
| 2021 Q4 | -209.53 Thousand GBP | 0.0% |
| 2021 Q2 | -301.23 Thousand GBP | -100.0% |
| 2021 Q1 | -150.61 Thousand GBP | -1889.91% |
| 2021 FY | -510.76 Thousand GBP | 0.0% |
| 2020 Q4 | -7569.00 GBP | 0.0% |
| 2020 Q3 | -7569.00 GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|